Waters Corporation (WAT) News
Follow Waters Corporation (WAT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 51 public stories across 19 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
WAT Reports Fiscal Q3 Shareholder Loss
WAT reported fiscal third-quarter profit attributable to shareholders of -1.27亿美元, down 130.46% year over year, with basic earnings per share of -1.37美元.
EQUITY | Nov 04, 2026, 05:42 AM UTC
M
Waters Corp Reports Quarterly Results for Quarter Ended September 30
EQUITY | Nov 03, 2026, 02:33 PM UTC
M
Waters CFO Expects 2026 Adjusted EBIT Margin of 28.2%
EARNINGS | Nov 03, 2026, 01:39 PM UTC
M
Waters Raises FY26 Organic Revenue Growth Guidance to 9.1%-9.7%
Waters’ CFO said the company raised its FY26 organic constant-currency revenue growth guidance by 140 basis points at the midpoint, to 9.1%-9.7%.
EARNINGS | Nov 03, 2026, 01:39 PM UTC
M
Waters Executive Sees Low-Teens Adjusted EPS Growth in 2027
An executive said low-teens adjusted EPS growth is the starting point for 2027, with mid-teens growth as an upside case.
EARNINGS | Nov 03, 2026, 01:37 PM UTC
M
Waters executive sees high-single-digit growth potential for combined company in 2027
A Waters executive said on a conference call that the combined company has high-single-digit growth potential in 2027.
EARNINGS | Nov 03, 2026, 01:36 PM UTC
M
Waters Reports Q3 2026 Revenue of $1.767 Billion, Adjusted EPS of $4.10
Waters reported $871 million in organic revenue and GAAP net income of $81 million, with diluted EPS of $0.82. It raised its full-year 202…
EQUITY | Nov 03, 2026, 01:22 PM UTC
M
Waters Executive Sees Biosciences Growth Benefit of About 200 Basis Points
An executive said China localization, better execution and DRG impact normalization are expected to benefit biosciences growth by about 200 basis points over the next several quarters.
EARNINGS | Nov 03, 2026, 01:18 PM UTC
M
Waters Reports Q3 Revenue of $1.767 Billion, Raises 2026 Guidance
Waters reported $1.767 billion in Q3 2026 revenue, including $871 million in organic revenue and $896 million from acquired businesses. Organic revenue rose 9% as reported and 10% in constant currency year over year. Adj
EQUITY | Nov 03, 2026, 12:32 PM UTC
M
Waters hikes FY forecasts as Q3 results beat
Waters raised its fiscal-year forecasts and reported third-quarter results that beat expectations.
EQUITY | Nov 03, 2026, 11:46 AM UTC
M
Waters Reports Higher Fiscal Q3 Earnings and Revenue, Raises 2026 Outlook
Waters reported fiscal Q3 non-GAAP earnings Tuesday, with revenue also higher. The company issued Q4 guidance and raised its fiscal 2026 outlook.
EQUITY | Nov 03, 2026, 11:26 AM UTC
M
Waters' Q3 Revenue and Adjusted EPS Beat Estimates
EQUITY | Nov 03, 2026, 11:12 AM UTC
M
Waters GAAP EPS Falls 67% in Third Quarter 2026
EARNINGS | Nov 03, 2026, 11:11 AM UTC
M
Waters Q3 Net Income Falls 46% to $81 Million
EARNINGS | Nov 03, 2026, 11:10 AM UTC
M
Waters Corp Reports Third-Quarter Revenue of $1.77B
EQUITY | Nov 03, 2026, 11:10 AM UTC
M
Waters Expects 2026 Revenue of $6.48B to $6.50B
Waters expects 2026 revenue of $6.48B to $6.50B, versus a FactSet estimate of $6.46B.
EARNINGS | Nov 03, 2026, 11:08 AM UTC
M
Waters Q3 Adjusted EPS $4.10 vs. IBES Estimate $4
EARNINGS | Nov 03, 2026, 11:03 AM UTC
M
Waters Issues Q4 Constant-Currency Sales Growth Outlook
EARNINGS | Nov 03, 2026, 11:03 AM UTC
M
Waters Provides FY Adjusted EPS Outlook
Waters' full-year adjusted EPS outlook is compared with an IBES estimate of $14.60.
EARNINGS | Nov 03, 2026, 11:02 AM UTC
M
Waters Sees FY Adjusted EPS of $14.60–$14.70
EARNINGS | Nov 03, 2026, 11:01 AM UTC
M
Waters Q3 Sales Reach USD 1,767 Million
Waters reported Q3 sales of USD 1,767 million versus an IBES estimate of USD 1,754 million.
EARNINGS | Nov 03, 2026, 11:01 AM UTC
M
Waters Reports Third-Quarter 2026 Financial Results
Waters announced its third-quarter 2026 financial results and said it will provide a starting 2027 growth framework on its earnings call.
EQUITY | Nov 03, 2026, 11:00 AM UTC
M
Waters Sees Fourth-Quarter Revenue of $1.8B-$1.82B
EARNINGS | Nov 03, 2026, 11:00 AM UTC
M
Waters Sees Fourth-Quarter Adjusted EPS of $4.58-$4.68
EARNINGS | Nov 03, 2026, 11:00 AM UTC
L
Waters reports third-quarter EPS
EARNINGS | Nov 03, 2026, 11:00 AM UTC
M
Waters Corp Sees FY Revenue of $6.48B-$6.5B
EARNINGS | Nov 03, 2026, 11:00 AM UTC
L
Waters Corp reports third-quarter net income of $81M
EARNINGS | Nov 03, 2026, 11:00 AM UTC
M
Waters Corp acquisition expands proteomics market entry
Waters Corp announced an acquisition that broadens its entry into the proteomics market.
MNA | Nov 03, 2026, 10:56 AM UTC
M
Waters Acquires Mobilion Systems
Waters said it acquired Mobilion Systems, adding ion-mobility separation technology to its mass spectrometry portfolio.
EQUITY | Nov 03, 2026, 10:56 AM UTC
M
Waters Q3 Earnings Preview: EPS Estimated at 4.00 USD
Waters is expected to report Q3 results on November 03 before the market opens, with revenue estimated at 1.75 billion USD and EPS at 4.00 USD.
EQUITY | Nov 02, 2026, 12:00 PM UTC
M
Waters Q3'26 Earnings Preview
Waters is scheduled to report Q3'26 results on November 3 before the market opens. Revenue and EPS estimates were provided.
EQUITY | Oct 27, 2026, 11:00 AM UTC
L
Waters launches AI Link for LC-MS workflows
Waters says AI Link advances LC-MS workflows from research to release.
EQUITY | Oct 13, 2026, 12:02 PM UTC
M
Waters Corporation Schedules Q3 2026 Earnings Call
Waters Corporation has announced the date for its third quarter 2026 earnings conference call.
EQUITY | Oct 01, 2026, 01:00 PM UTC
L
Weekly Recap: Q2 BD COR high—throughput installs and Goldman Sachs $515 target
Waters Corporation (NYSE:WAT) is accelerating Q2 momentum with 15 BD COR high—throughput installs and plans to migrate more assays from BD MAX plus add an HPV home/self—test option, while Goldman Sachs reiterates a Buy a
NEWS | Sep 28, 2026, 11:06 AM UTC
H
WAT outlook supported by localization, pricing and integration momentum
TradingView reports strong Q2 results led by growth across instruments, recurring revenue and chemistry. China and pharma segments outperformed, while localization, pricing improvements and integration synergies support
EARNINGS | Sep 09, 2026, 03:55 PM UTC
H
WAT flags broad growth and China momentum after strong Q2
WAT says Q2 strength reflected broad-based growth across instruments, chemistry and diagnostics, with China and acquired businesses outperforming expectations. It cites integration synergies ahead of plan and expects sus
EARNINGS | Sep 09, 2026, 03:19 PM UTC
L
UBS raises Waters Corp price target to $490 from $375
UBS raised its price target on Waters Corp to $490.00 per share from $375.00, according to ratings actions cited by Benzinga.
EQUITY | Sep 09, 2026, 01:44 PM UTC
M
WAT statutory NPAT up 59%; EBIT margins expand
WAT reported statutory NPAT rose 59% and EBIT margins expanded, citing international growth and operational efficiencies.
EQUITY | Aug 31, 2026, 10:53 PM UTC
L
Waters price target raised to $480 by Piper Sandler
Waters Corp price target raised to $480.00 per share from $400.00 by Piper Sandler.
EQUITY | Aug 27, 2026, 04:52 PM UTC
L
Waters to present at Wells Fargo Healthcare conference
Waters Corporation said it will present at the Wells Fargo Healthcare Conference.
EQUITY | Aug 26, 2026, 01:01 PM UTC
H
Analysts Upgrade ADM, AEIS, CPNG, ENTG, KTOS, PLD, RA, VGNT, WAT
Multiple stocks upgraded by analysts
EQUITY | Aug 05, 2026, 10:59 AM UTC
H
Waters Q2 Sales $828M, Misses Estimate
Waters reports Q2 sales of $828M, below estimate
EARNINGS | Aug 04, 2026, 10:22 AM UTC
H
WAT Reports Q2 EPS 3.05
WAT beats Q2 EPS estimates
EARNINGS | Aug 04, 2026, 10:04 AM UTC
H
Waters Raises FY2026 Adj EPS Guidance from $14.40-$14.60 to $14.45-$14.65 vs $14.51 Est; Raises FY2026 Sales Guidance from $6.405B-$6.455B t
Waters (NYSE: WAT ) raises FY2026 Adj EPS guidance from $14.40-$14.60 to $14.45-$14.65 vs $14.51 analyst estimate. Raises FY2026 sales outlook from $6.405 billion-$6.455 billion to $6.415 billion-$6.476 billion vs $6.436
EARNINGS | Aug 04, 2026, 10:03 AM UTC
H
WAT - Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results
WAT - Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 04, 2026, 10:01 AM UTC
L
WAT - Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer - Click For Re
WAT - Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
EQUITY | Jul 27, 2026, 12:11 PM UTC
L
TMO DHR WAT A in Tools and GH CAI in Diagnostics remain Buy rated in Q2 preview @ GSCO
TMO DHR WAT A in Tools and GH CAI in Diagnostics remain Buy rated in Q2 preview @ GSCO
EQUITY | Jul 15, 2026, 12:17 PM UTC
H
Waters price target raised to $390 from $350 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh raised the firm's price target on Waters to $390 from $350 and keeps an Equal Weight rating on the shares. The firm is updating its model ahead of the earnings report.
EQUITY | Jul 09, 2026, 11:00 AM UTC
L
Evercore ISI Adjusts Price Target on Waters to $410 From $380
() -- Waters (WAT) has an average rating of overweight and mean price target of $406.52, according to analysts polled by FactSet. ( covers equity, commodity and economic research from major banks and research firms in No
EQUITY | Jul 06, 2026, 01:06 PM UTC
M
WAT: Bernstein Reinstates Outperform
Bernstein analyst Eve Burstein reinstates Waters with an Outperform rating and $435 price target.
EQUITY | Jun 26, 2026, 01:14 PM UTC
L
WAT - IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precis
WAT - IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
EQUITY | Jun 24, 2026, 12:02 PM UTC